MIRIAM EZENWAKA: Open Payments
NPI 1356061717 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,180 in 145 payments from 11 companies in 2025. Trend: 2023 $71 · 2024 $2,301 · 2025 $3,180
Food & beverage: $3,180
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $568 |
| E.R. Squibb & Sons, L.L.C. | 25 | $448 |
| Alkermes, Inc. | 21 | $407 |
| Teva Pharmaceuticals USA, Inc. | 18 | $390 |
| Vanda Pharmaceuticals Inc. | 9 | $317 |
| Lundbeck LLC | 14 | $279 |
| Neurocrine BioSciences, Inc. | 9 | $267 |
| Otsuka America Pharmaceutical, Inc. | 9 | $202 |
| ABBVIE INC. | 9 | $162 |
| Janssen Pharmaceuticals, Inc | 3 | $118 |
Products named: CAPLYTA, COBENFY, ARISTADA, ABILIFY ASIMTUFII, INGREZZA, UZEDY, REXULTI, HETLIOZ.
Industry payments across DC — which companies pay providers there.
